Steven Cohen Y M Abs Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 95,383 shares of YMAB stock, worth $609,497. This represents 0.0% of its overall portfolio holdings.

Number of Shares

95,383

Previous 358,945 73.43%

Holding current value

$609,497

Previous $4.34 Million 71.13%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$9.95 - $15.39 $2.62 Million - $4.06 Million	-263,562 Reduced 73.43%	95,383 $1.25 Million
Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.25 $13.6 Million - $20.2 Million	-1,168,155 Reduced 76.49%	358,945 $4.34 Million
Q1 2024 May 15, 2024	BUY	$6.57 - $18.69 $10 Million - $28.5 Million	1,527,100 New	1,527,100 $24.8 Million
Q3 2023 Nov 14, 2023	SELL	$4.86 - $7.23 $1.48 Million - $2.2 Million	-303,987 Reduced 79.25%	79,600 $433,000
Q2 2023 Aug 14, 2023	BUY	$5.68 - $10.34 $149,775 - $272,655	26,369 Added 7.38%	383,587 $2.6 Million
Q1 2023 May 15, 2023	SELL	$2.83 - $5.11 $260,959 - $471,203	-92,212 Reduced 20.52%	357,218 $1.79 Million
Q4 2022 Feb 14, 2023	BUY	$3.0 - $15.17 $1.35 Million - $6.82 Million	449,430 New	449,430 $2.19 Million
Q3 2019 Nov 15, 2019	SELL	$21.57 - $31.37 $647,100 - $941,100	-30,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$19.51 - $28.31 $585,300 - $849,300	30,000 New	30,000 $686,000
Q4 2018 Feb 14, 2019	SELL	$15.41 - $28.92 $77,050 - $144,600	-5,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$24.0 - $26.97 $120,000 - $134,850	5,000 New	5,000 $133,000

Others Institutions Holding YMAB

# of Institutions

107

Shares Held

24.5M

Call Options Held

40.3K

Put Options Held

400

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $279M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account